Accelerated tumour growth due to immunotherapy: Fact or fiction?
Biomarkers of systemic inflammation linked to reduced clinical activity of atezolizumab monotherapy in metastatic TNBC
KEYNOTE-028 and KEYNOTE-158: Pembrolizumab as treatment for advanced SCLC after two or more lines of prior therapy
5' UTR mutations in prostate cancer
Cancer preventive vaccine used in mouse model of Lynch syndrome
ADMIRAL: Gilteritinib as treatment for patients with relapsed or refractory acute myeloid leukaemia
Immunomodulatory effects of PARP inhibition in BRCA1-deficient triple-negative breast cancer
Talimogene laherparepvec combined with neoadjuvant chemotherapy for non-metastatic triple negative breast cancer
Efficacy and immune correlates of the SRA737 plus LDG regimen in combination with anti-PD-L1 in an SCLC model
Lymphodepleting chemotherapy in order to safely improve the expansion of HER2-CAR T cells in patients with advanced sarcomas
Evaluation of M7824, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with HPV-associated malignancies
TATTON: Osimertinib plus savolitinib for patients with EGFR-mutant, MET-amplified NSCLC after progression on EGFR-TKI
Combining the SLP vaccine with chemo-immunotherapy in order to increase the HPV-specific T-cell response in cervical cancer
Umbralisib as a monotherapy in patients with relapsed/refractory marginal zone lymphoma
Tumour shrinkage with ipilimumab plus nivolumab in patients with neuroendocrine carcinoma
TATTON: Updated results for patients with EGFR-mutant NSCLC
Cancer preventive vaccine showed promising results in preclinical model of Lynch syndrome
HER2-targeted CAR T-cell therapy safe and showing promising antitumour activity in patients with advanced sarcoma
Mesothelin-targeted CAR T-cell therapy safe, shows early promise in patients with advanced solid tumours
KEYNOTE trials show pembrolizumab benefited patients with advanced small cell lung cancer
